• linkedin
  • Increase Font
  • Sharebar

    Omnibus Guidelines expected to bring changes to the 340B program

    Ned MilenkovichNed MilenkovichThe 340B Drug Pricing Program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations and covered entities at reduced prices. The intent of the program is to “stretch scarce federal resources” by easing costs for providers who deliver care to enrollees in government programs.

    Program eligibility has been expanded several times since the law’s inception in 1992. Covered entities must identify as nonprofit healthcare organizations and have certain federal designations or receive funding from specific federal programs. Currently, covered entities include federally qualified health centers, Ryan White HIV/AIDS Program grantees, and certain types of hospitals and specialized clinics.

    The program also has established some criteria for individuals to receive status as “Qualified Patients.” Currently, Qualified Patients must establish a relationship with a 340B covered entity. The relationship must include retention of patient documents by the covered entity, provision of healthcare by professionals employed by the covered entity, and designation of care provided as a type for which the entity receives grant funding or status as a federally qualified health center.

    As the program has continued to expand, most significantly with the adoption of the Affordable Care Act in 2010, the ambiguities at the heart of the program have grown to create more significant problems. Factors that have contributed to the program’s expansion “beyond its bounds” include the broad definition of Qualified Patients and scattered hospital eligibility criteria. The 2015 guidelines are expected to clarify many of the current ambiguities.

    See also: First biosimilar finally approved by FDA

    340B Omnibus Guidelines

    The Office of Management and Budget has begun its 90-day review of the 340B Program Omnibus Guidelines issued by the Health Resources and Services Administration (HRSA). These guidelines are expected to address many of the issues included in last year’s 340B “mega-reg.”

    The 2014 proposed guidance was withdrawn after a court decision pertaining to an unrelated 340B issue called into question HRSA’s authority to create regulations on certain topics included in the 2014 guidance document. The federal case held that HRSA has regulatory authority only over the 340B Program: ceiling prices, dispute resolution processes, and manufacturer monetary penalties.

    After the federal court’s ruling, HRSA changed strategies, shifting from proposed regulations to issuing guidance in the form of guidelines. This allowed HRSA to extend the scope of the guidance document beyond the limited topics identified by the court.

    Ned Milenkovich, PharmD, JD
    This article is not intended as legal advice and should not be used as such. When legal questions arise, pharmacists should consult with ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available